Orgenesis Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Orgenesis Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $34.74M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $35.50M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $7.65M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $3.90M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $1.85M | Mar 9, 2020 |
| FY2019 | Nov 30, 2018 | $18.66M | Mar 9, 2020 |
| FY2019 | Dec 31, 2017 | $802.0K | Mar 9, 2020 |
| FY2018 | Nov 30, 2017 | $10.09M | Feb 13, 2019 |
| FY2017 | Nov 30, 2016 | $6.40M | Feb 28, 2018 |
| FY2016 | Nov 30, 2015 | $2.97M | Feb 28, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.04M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $530.0K | Mar 26, 2026 |
| FY2023 | Dec 31, 2022 | $36.03M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $31.65M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $6.18M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $2.63M | Mar 9, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($893.0K) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($5.73M) | Mar 26, 2026 |
| FY2023 | Dec 31, 2022 | $30.89M | Apr 15, 2024 |
| FY2018 | Nov 30, 2018 | $7.83M | Feb 13, 2019 |
| FY2018 | Nov 30, 2017 | $3.28M | Feb 13, 2019 |
| FY2017 | Nov 30, 2016 | ($1.26M) | Feb 28, 2018 |
| FY2016 | Nov 30, 2015 | ($906.0K) | Feb 28, 2017 |
| FY2015 | Nov 30, 2014 | $0 | Feb 29, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($48.17M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($55.36M) | Mar 26, 2026 |
| FY2023 | Dec 31, 2022 | ($14.89M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($18.05M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $1.11M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $24.12M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($2.74M) | Mar 9, 2020 |
| FY2019 | Nov 30, 2018 | ($18.29M) | Mar 9, 2020 |
| FY2018 | Nov 30, 2017 | ($12.37M) | Feb 13, 2019 |
| FY2017 | Nov 30, 2016 | ($11.11M) | Feb 28, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($39.77M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($53.64M) | Mar 26, 2026 |
| FY2023 | Dec 31, 2022 | ($10.11M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($16.80M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($95.79M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $21.98M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($2.96M) | Mar 9, 2020 |
| FY2019 | Nov 30, 2018 | ($13.92M) | Mar 9, 2020 |
| FY2019 | Dec 31, 2017 | ($1.35M) | Mar 9, 2020 |
| FY2018 | Nov 30, 2017 | ($11.23M) | Feb 13, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $9.62M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $10.62M | Mar 26, 2026 |
| FY2023 | Dec 31, 2022 | $21.93M | Apr 15, 2024 |
| FY2021 | Dec 31, 2021 | $36.64M | Mar 30, 2022 |
| FY2021 | Dec 31, 2020 | $83.99M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $14.01M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $1.43M | Mar 9, 2020 |
| FY2019 | Nov 30, 2018 | $6.46M | Mar 9, 2020 |
| FY2018 | Nov 30, 2017 | $2.48M | Feb 13, 2019 |
| FY2017 | Nov 30, 2016 | $2.16M | Feb 28, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $14.82M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $35.13M | Mar 26, 2026 |
| FY2023 | Dec 31, 2022 | $15.59M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $14.71M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $18.97M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $11.45M | Mar 9, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($17.08M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($14.84M) | Mar 26, 2026 |
| FY2023 | Dec 31, 2022 | ($24.92M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($26.87M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($78.05M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($13.22M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($1.08M) | Mar 9, 2020 |
| FY2019 | Nov 30, 2018 | ($15.68M) | Mar 9, 2020 |
| FY2018 | Nov 30, 2017 | ($3.83M) | Feb 13, 2019 |
| FY2017 | Nov 30, 2016 | ($3.78M) | Feb 28, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $263.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $2.10M | Mar 26, 2026 |
| FY2023 | Dec 31, 2022 | $12.42M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $7.87M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $1.53M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $12.13M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $535.0K | Mar 9, 2020 |
| FY2019 | Nov 30, 2018 | $5.56M | Mar 9, 2020 |
| FY2018 | Nov 30, 2017 | $975.0K | Feb 13, 2019 |
| FY2017 | Nov 30, 2016 | $1.43M | Feb 28, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.35M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $14.55M | Mar 26, 2026 |
| FY2023 | Dec 31, 2022 | $90.93M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $59.84M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $77.68M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $92.50M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $73.88M | Mar 9, 2020 |
| FY2018 | Nov 30, 2018 | $75.45M | Feb 13, 2019 |
| FY2018 | Nov 30, 2017 | $39.87M | Feb 13, 2019 |
| FY2017 | Nov 30, 2016 | $33.49M | Feb 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $38.88M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $35.54M | Mar 26, 2026 |
| FY2023 | Dec 31, 2022 | $31.65M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $21.21M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $24.96M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $55.46M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $22.90M | Mar 9, 2020 |
| FY2018 | Nov 30, 2018 | $22.65M | Feb 13, 2019 |
| FY2018 | Nov 30, 2017 | $22.14M | Feb 13, 2019 |
| FY2017 | Nov 30, 2016 | $20.99M | Feb 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($37.50M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($20.98M) | Mar 26, 2026 |
| FY2023 | Dec 31, 2022 | $27.56M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $38.49M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $52.58M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $5.48M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $26.11M | Mar 9, 2020 |
| FY2018 | Nov 30, 2018 | $28.35M | Feb 13, 2019 |
| FY2018 | Nov 30, 2017 | $14.12M | Feb 13, 2019 |
| FY2017 | Nov 30, 2016 | $12.50M | Feb 28, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $1.21M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $8.19M | Mar 26, 2026 |
| FY2023 | Dec 31, 2021 | $8.40M | Apr 15, 2024 |
| FY2022 | Dec 31, 2020 | $8.75M | Mar 22, 2023 |
| FY2021 | Dec 31, 2019 | $4.81M | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $4.94M | Mar 9, 2021 |
| FY2019 | Nov 30, 2018 | $15.17M | Mar 9, 2020 |
| FY2019 | Nov 30, 2017 | $10.68M | Mar 9, 2020 |
| FY2018 | Nov 30, 2016 | $9.58M | Feb 13, 2019 |
| FY2016 | Nov 30, 2015 | $9.54M | Feb 28, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($224.79M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($176.62M) | Mar 26, 2026 |
| FY2023 | Dec 31, 2022 | ($121.26M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($106.37M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($88.32M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($89.43M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($65.16M) | Mar 9, 2020 |
| FY2018 | Nov 30, 2018 | ($62.41M) | Feb 13, 2019 |
| FY2018 | Nov 30, 2017 | ($44.12M) | Feb 13, 2019 |
| FY2017 | Nov 30, 2016 | ($31.75M) | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $78.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $837.0K | Mar 26, 2026 |
| FY2023 | Dec 31, 2022 | $5.31M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $5.47M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $44.92M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $107.0K | Mar 9, 2021 |
| FY2018 | Nov 30, 2018 | $16.46M | Feb 13, 2019 |
| FY2018 | Nov 30, 2017 | $3.52M | Feb 13, 2019 |
| FY2018 | Nov 30, 2016 | $891.0K | Feb 13, 2019 |
| FY2017 | Nov 30, 2015 | $4.17M | Feb 28, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 11 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 19 | Mar 26, 2026 |
| FY2023 | Dec 31, 2022 | 0 | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 1 | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 9, 2020 |
| FY2019 | Nov 30, 2018 | (1) | Mar 9, 2020 |
| FY2019 | Dec 31, 2017 | 0 | Mar 9, 2020 |
| FY2018 | Nov 30, 2017 | (1) | Feb 13, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 11 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 19 | Mar 26, 2026 |
| FY2023 | Dec 31, 2022 | 0 | Apr 15, 2024 |
| FY2019 | Dec 31, 2019 | (1) | Mar 9, 2020 |
| FY2019 | Dec 31, 2018 | 0 | Mar 9, 2020 |
| FY2019 | Nov 30, 2018 | (1) | Mar 9, 2020 |
| FY2019 | Dec 31, 2017 | 0 | Mar 9, 2020 |
| FY2018 | Nov 30, 2017 | (1) | Feb 13, 2019 |
| FY2017 | Nov 30, 2016 | 1 | Feb 28, 2018 |
| FY2016 | Nov 30, 2015 | 0 | Feb 28, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 5.17M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 3.19M | Mar 26, 2026 |
| FY2023 | Dec 31, 2022 | 25.55M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | 24.28M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | 24.17M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 16.14M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | 15.54M | Mar 9, 2020 |
| FY2018 | Nov 30, 2018 | 14.95M | Feb 13, 2019 |
| FY2018 | Nov 30, 2017 | 9.87M | Feb 13, 2019 |
| FY2017 | Nov 30, 2016 | 9.51M | Feb 28, 2018 |